NCT07303907Phase 2Completed

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

Study sponsor: Definium Therapeutics US, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09-16Actual
Enrollment · participants5Actual
Source updated2026-11-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 20 participants (planned). After: 5 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2027. After: 16 Sep 2026.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source